A Phase 3 randomized Double-blind Placebo-controlled study of ARQ 197 plus erlotinib versys polacebo plus erlotinib in previously treated subjects with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC)
|Effective start/end date||11/1/10 → 6/1/13|
- Daiichi Sankyo Company, Limited
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.